Common questions about our human TGF-β Luminex multiplex panel service.
Why is acid activation required for TGF-β measurement?
TGF-β is unique among cytokines: it is secreted as a latent complex in which the mature, bioactive TGF-β dimer is non-covalently bound to its Latency-Associated Peptide (LAP), which masks the receptor-binding epitope. Without acid activation, detection antibodies cannot access the mature TGF-β dimer — the assay would measure only the small fraction (<5%) that has spontaneously activated in the sample. Acidification (pH ~2–3) dissociates LAP, exposing the mature TGF-β for antibody binding. After neutralization (pH ~7.4), the now-exposed active TGF-β is quantified by sandwich immunoassay. This is a validated, manufacturer-standardized protocol specifically designed for TGF-β measurement.
What is the difference between LAP (TGF-β1) and the active TGF-β1 measured in this panel?
LAP (TGF-β1) is the Latency-Associated Peptide that is cleaved from the pro-TGF-β1 precursor during maturation but remains bound to the mature TGF-β1 dimer in the latent complex. Our Cardiac Remodeling 8-Plex Panel measures LAP without acid activation, reflecting the amount of latent TGF-β1 present. This TGF-β 3-Plex measures the mature, bioactive TGF-β dimer after acid activation, reflecting the total pool of activatable TGF-β. The two measurements are complementary: LAP indicates how much latent TGF-β1 exists; the 3-Plex indicates how much active TGF-β can be generated from all three isoforms.
Why measure TGF-β2 and TGF-β3 — isn't TGF-β1 sufficient?
TGF-β1 is the most abundant isoform in the immune system and is the primary focus of most fibrosis and immunology research. However, TGF-β2 and TGF-β3 have distinct — and sometimes opposing — biological functions. TGF-β2 is independently implicated in Marfan syndrome, glioma immune evasion, and glaucoma. TGF-β3 promotes scarless wound healing and may antagonize TGF-β1-driven fibrosis. In acute coronary syndrome, all three isoforms are simultaneously reduced, suggesting a global TGF-β system effect. Measuring only TGF-β1 provides an incomplete picture and misses isoform-specific dysregulation that is therapeutically relevant.
Should I use serum or plasma for TGF-β measurement?
The choice depends on your research question. Serum TGF-β1 levels are 2–5 fold higher than plasma because platelets release large quantities of TGF-β1 during the clotting process. If your study aims to measure total TGF-β (including platelet-derived), serum is appropriate. If you are measuring circulating TGF-β that reflects ongoing endothelial or immune cell production, platelet-poor plasma is preferred. The critical rule is: choose one matrix and use it consistently across all samples in your study. Never mix serum and plasma within the same analysis.
Can I measure % active TGF-β without acid activation?
Yes. By running each sample twice on the same plate — once with acid activation (total TGF-β) and once without (spontaneously active TGF-β) — you can calculate the percentage of TGF-β that is already in its active form. This approach is valuable for tissue culture experiments and tumor microenvironment research where you need to distinguish latent from active TGF-β. Contact us to configure this parallel measurement option for your study.
How stable are acid-activated samples?
After acid activation and neutralization, samples are stable at 2–8°C for up to 24 hours. Do NOT freeze activated samples — freeze-thaw can cause TGF-β re-aggregation and loss of immunoreactivity. We recommend planning your assay timing so that acid activation is performed on the day of the assay. Original (un-activated) samples can be stored at -80°C long-term.
Can this panel be used for non-human species?
Yes. The TGF-β 3-Plex panel is validated for multiple species including mouse, rat,
non-human primate, canine, feline, porcine, equine,
guinea pig, and hamster. The high degree of TGF-β sequence conservation across mammals (>95% in the mature domain) enables cross-species reactivity. If your research involves non-standard species, contact us to discuss validation requirements.
What concentration ranges should I expect for TGF-β isoforms in human serum?
In healthy human serum following acid activation, TGF-β1 is typically the dominant isoform at 10–50 ng/mL (reflecting platelet-derived TGF-β1). TGF-β2 and TGF-β3 are present at lower concentrations (typically 0.1–5 ng/mL). In plasma (platelet-poor), levels are 2–5 fold lower for TGF-β1. Disease states can significantly alter these ranges: TGF-β1 may be elevated in fibrosis and cancer, while all three isoforms are diminished in acute coronary syndrome. The standard curve range (9.8–10,000 pg/mL) accommodates both normal and pathological concentrations with appropriate dilution.
